Praxis Precision Medicines Inc - ESG Rating & Company Profile powered by AI
Full Sustainability analysis of Praxis Precision Medicines Inc can be reached by signing up for free. Other companies in the rating industry group for Praxis Precision Medicines Inc are shownin the table. If you work at Praxis Precision Medicines Inc and you wish to use your ESG aseessment, please get in touch.
Praxis Precision Medicines Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.8; made up of an environmental score of 2.0, social score of 3.2 and governance score of 3.2.
2.8
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1353 | Vera Therapeutics Inc | 2.9 | Medium |
1353 | Veracyte Inc | 2.9 | Medium |
1393 | Praxis Precision Medicines Inc | 2.8 | Medium |
1393 | Bioventix PLC | 2.8 | Medium |
1393 | Bolt Biotherapeutics Inc | 2.8 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Praxis Precision Medicines Inc have an accelerator or VC vehicle to help deliver innovation?
Does Praxis Precision Medicines Inc disclose current and historical energy intensity?
Does Praxis Precision Medicines Inc report the average age of the workforce?
Does Praxis Precision Medicines Inc reference operational or capital allocation in relation to climate change?
Does Praxis Precision Medicines Inc disclose its ethnicity pay gap?
Does Praxis Precision Medicines Inc disclose cybersecurity risks?
Does Praxis Precision Medicines Inc offer flexible work?
Does Praxis Precision Medicines Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Praxis Precision Medicines Inc disclose the number of employees in R&D functions?
Does Praxis Precision Medicines Inc conduct supply chain audits?
Does Praxis Precision Medicines Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Praxis Precision Medicines Inc conduct 360 degree staff reviews?
Does Praxis Precision Medicines Inc disclose the individual responsible for D&I?
Does Praxis Precision Medicines Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Praxis Precision Medicines Inc disclose current and / or historical scope 2 emissions?
Does Praxis Precision Medicines Inc disclose water use targets?
Does Praxis Precision Medicines Inc have careers partnerships with academic institutions?
Did Praxis Precision Medicines Inc have a product recall in the last two years?
Does Praxis Precision Medicines Inc disclose incidents of discrimination?
Does Praxis Precision Medicines Inc allow for Work Councils/Collective Agreements to be formed?
Has Praxis Precision Medicines Inc issued a profit warning in the past 24 months?
Does Praxis Precision Medicines Inc disclose parental leave metrics?
Does Praxis Precision Medicines Inc disclose climate scenario or pathway analysis?
Does Praxis Precision Medicines Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Praxis Precision Medicines Inc disclose the pay ratio of women to men?
Does Praxis Precision Medicines Inc support suppliers with sustainability related research and development?
Does Praxis Precision Medicines Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Praxis Precision Medicines Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Praxis Precision Medicines Inc involved in embryonic stem cell research?
Does Praxis Precision Medicines Inc disclose GHG and Air Emissions intensity?
Does Praxis Precision Medicines Inc disclose its waste policy?
Does Praxis Precision Medicines Inc report according to TCFD requirements?
Does Praxis Precision Medicines Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Praxis Precision Medicines Inc disclose energy use targets?
Does Praxis Precision Medicines Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Praxis Precision Medicines Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Praxis Precision Medicines Inc
These potential risks are based on the size, segment and geographies of the company.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.